Funding, News and Announcements
» Go to news mainPfizer RFP Closing the Homologous Recombination Repair gene mutation HRRm Testing Gap in Prostate Cancer Patients
Applicants should submit proposals bringing solutions for the expansion of HRRm testing in Canadian prostate cancer patients. Ideally, these will be projects with short-term impact, aimed at closing areas of large gaps. This may include, but not limited to:
- The development of solutions reducing inequities in access to HRRm tests in currently underserved regions or populations
- The development of solutions for early HRRm testing in patients with metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- The development of solutions addressing important areas of inefficiencies or issues related to HRRm testing (any stages from test request to report results)
- The development of solutions to measure the evolution and performance of HRRm testing in Canadian real-world practice against current guidelines
Funding Range:
- Individual projects requesting up to a maximum of CAD $100,000 will be considered.
- The total available budget related to this RFP is CAD $200,000.
Full details about this call are available here.
Internal Deadline: April 18, 2024 at 4:30pm. Contact email is ird@dal.ca.
Funder Deadline: May 2, 2024. Contact is Lori.Carpenter@pfizer.com, with the subject line “Closing the HRRm Testing Gap in Prostate Cancer Patients 20 February 2024”